2658-6533Research Results in Biomedicine2658-653310.18413/2658-6533-2019-5-2-0-41677GeneticsAnalysis of the association between C936T VEGFA gene polymorphism and diabetic foot syndrome in the Ukrainian populationAnalysis of the association between C936T VEGFA gene polymorphism and diabetic foot syndrome in the Ukrainian populationRusanovAlexandr V.RusanovAlexandr V.rusanov_ol@ukr.netChumachenkoYaroslav D.ChumachenkoYaroslav D.yaroslavus.dm@gmail.comDubovykEvgeniy I.DubovykEvgeniy I.janitor@ukr.netHarbuzovaVictoriia Yu.HarbuzovaVictoriia Yu.v.garbuzova@med.sumdu.edu.uaAtamanAlexandr V.AtamanAlexandr V.olex0101@gmail.com20195200

Background: The dysfunction of vascular endothelial growth factor A (VEGFA) is one of the leading factors of macro- and microangiopathy development in diabetic foot syndrome (DFS) patients. Recently, a number of experimental studies in various populations have been carried out to test the association between VEGFA gene polymorphisms and development of chronic hyperglycemia vascular complications. At the same time, there are no such studies in Ukrainian population. The aim of the study: The aim of this work was to check the possible association between C936T VEGFA gene polymorphism and DFS development in Ukrainian patients with type 2 diabetes mellitus (T2DM). Materials and methods: Venous blood of 154 patients with T2DM complicated by DFS and 124 individuals without diabetes and glucose intolerance was used. The polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP) was performed for VEGFA C936T (rs3025039) polymorphism genotyping. SPSS-17 was used for most statistical analyses. Results: It was found that ratio of C/C-homozygotes, C/T-heterozygotes and T/T-homozygotes (C936T VEGFA gene polymorphism) in patients with DFS was 47.4%, 41.6% and 11.0%; in the control group – 50.0%, 43.5%, 6.5%, respectively. Comparison of these genotypes frequencies between DFS patients and control subjects using χ2-Pearson criterion showed no significant difference (P = 0.413). The results of regression analysis under the dominant, recessive, superdominant and additive inheritance models also revealed no association between VEGFA C936T genotypes and DFS development (P>0.05). Conclusion: There is no link between VEGFA C936T polymorphism and risk of DFS development in Ukrainian patients with T2DM.

Background: The dysfunction of vascular endothelial growth factor A (VEGFA) is one of the leading factors of macro- and microangiopathy development in diabetic foot syndrome (DFS) patients. Recently, a number of experimental studies in various populations have been carried out to test the association between VEGFA gene polymorphisms and development of chronic hyperglycemia vascular complications. At the same time, there are no such studies in Ukrainian population. The aim of the study: The aim of this work was to check the possible association between C936T VEGFA gene polymorphism and DFS development in Ukrainian patients with type 2 diabetes mellitus (T2DM). Materials and methods: Venous blood of 154 patients with T2DM complicated by DFS and 124 individuals without diabetes and glucose intolerance was used. The polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP) was performed for VEGFA C936T (rs3025039) polymorphism genotyping. SPSS-17 was used for most statistical analyses. Results: It was found that ratio of C/C-homozygotes, C/T-heterozygotes and T/T-homozygotes (C936T VEGFA gene polymorphism) in patients with DFS was 47.4%, 41.6% and 11.0%; in the control group – 50.0%, 43.5%, 6.5%, respectively. Comparison of these genotypes frequencies between DFS patients and control subjects using χ2-Pearson criterion showed no significant difference (P = 0.413). The results of regression analysis under the dominant, recessive, superdominant and additive inheritance models also revealed no association between VEGFA C936T genotypes and DFS development (P>0.05). Conclusion: There is no link between VEGFA C936T polymorphism and risk of DFS development in Ukrainian patients with T2DM.

diabetic foot syndromegene polymorphismVEGFAdiabetic foot syndromegene polymorphismVEGFA

The work is an integral part of the research theme «Molecular genetic and morphological features of the regeneration of lower limb tissues under chronic hyperglycemia» (state registration number 0117U003926)

Список литературыVolmer-Thole M, Lobmann R. Neuropathy and Diabetic Foot Syndrome. Int J Mol Sci. 2016 Jun;17(6):917. DOI: https://doi.org/10.3390/ijms17060917Yehuda H. Updated Clinical Recommendations on diagnostics and treatment of diabetes mellitus American Association of Clinical Endocrinology (AACE) and American College of Endocrinology (ACE), 2015. Diabetes. Adiposity. Metabolic syndrome. 2015 Feb 12;4(6):17-21.Amin N, Doupis J. Diabetic foot disease: From the evaluation of the “foot at risk” to the novel diabetic ulcer treatment modalities. World J Diabetes. 2016 Apr 10;7(7):153-164. DOI: 10.4239/wjd.v7.i7.153Permutt M, Wasson J, Cox N. Genetic epidemiology of diabetes. J Clin Invest. 2005 Jun 1;115(6):1431-1439. DOI: 10.1172/JCI24758Zachary I, Mathur A, Yla-Herttuala S, et al. Vascular protection: A novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1512-20. DOI: https://doi.org/10.1161/01.ATV.20.6.1512Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007 Jun 18;96(12):1788-95. DOI: https://doi.org/10.1038/sj.bjc.6603813Qu Y, Dai H, Zhou F, et al. Vascular endothelial growth factor gene polymorphisms and risk of neovascular age-related macular degeneration in a Chinese cohort. Ophthalmic Res. 2011;45(3):142-8. DOI: 10.1159/000319543Klimontov VV, Tyan NV, Orlov NB, et al. Association of Serum Levels and Gene Polymorphism of Vascular Endothelium Growth Factor with Ischemic Heart Disease in Type 2 Diabetic Patients. Kardiologiya. 2017 May;57(5):17-22.Sellami N, Lamine LB, Turki A, et al. Association of VEGFA variants with altered VEGF secretion and type 2 diabetes: A case-control study. Cytokine. 2018 Jun;106:29-34. DOI: https://doi.org/10.1016/j.cyto.2018.03.003Han L, Zhang L, Xing W, et al. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: a meta-analysis of 11 case-control studies. J Diabetes Res. 2014;2014:805801. DOI: http://dx.doi.org/10.1155/2014/805801Renner W, Kotschan S, Hoffmann C, et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000 Nov-Dec;37(6):443-8. DOI: 10.1159 / 000054076Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 2003 Sep 10;106(4):468-71. DOI: https://doi.org/10.1002/ijc.11238Li X, Lu Y, Wei P. Association between VEGF genetic variants and diabetic foot ulcer in Chinese Han population: A case-control study. Medicine (Baltimore). 2018 May;97(20):e10672. DOI: 10.1097 / MD.0000000000010672Li X. The association between MCP-1, VEGF polymorphisms and their serum levels in patients with diabetic foot ulcer. Medicine (Baltimore). 2018 Jun;97(24):e10959. DOI: 10.1097 / MD.0000000000010959Amoli MM, Hasani-Ranjbar S, Roohipour N, et al. VEGF gene polymorphism association with diabetic foot ulcer. Diabetes Res Clin Pract. 2011 Aug;93(2):215-9. DOI: https://doi.org/10.1016/j.diabres.2011.04.016